Biotech | November 26, 2025
Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Jaypirca is making waves in the fight against B-cell malignancies
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Winlevi is authorized in EU for the treatment of acne vulgaris
Subscribe To Our Newsletter & Stay Updated
